Analyst firms · Oppenheimer · BIIB

Oppenheimer BIIB price target and rating history

Biogen Inc. (BIIB) · Health Care

Oppenheimer rates Biogen Inc. (BIIB) Outperform with a $285 price target, as of its latest action on Feb 4, 2022. It has published 3 rating actions on BIIB since October 2021, including 0 upgrades and 0 downgrades. Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50.

Current rating
Outperform
Price target
$285
Median target, all firms
$231.50
Actions on BIIB
3

Oppenheimer price target on BIIB

$390$338$28520222023202420252026
Oppenheimer price target on BIIB, each point a stated target, October 2021 to February 2022.

Every Oppenheimer rating on BIIB

How other firms rate BIIB

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Argus ResearchBuy$280Oct 29, 2026
Wolfe ResearchOutperform$300Aug 13, 2026
Truist SecuritiesBuy$235Jul 13, 2026
NeedhamBuy$255Jun 8, 2026
Evercore ISIOutperformMay 15, 2026
UBSBuy$225Apr 22, 2026
Wells FargoOverweight$250Apr 20, 2026
Piper SandlerOverweight$214Apr 14, 2026
BarclaysEqual Weight$185Feb 20, 2026
H.C. WainwrightBuy$228Feb 9, 2026
HSBCReduce$143Dec 10, 2025

Questions about Oppenheimer and BIIB

What is Oppenheimer's price target for BIIB?
Oppenheimer's latest stated price target for Biogen Inc. (BIIB) is $285, from its action on Feb 4, 2022.
What is Oppenheimer's rating on BIIB?
Oppenheimer rates BIIB Outperform, a bullish rating, as of Feb 4, 2022.
When did Oppenheimer last change its view on BIIB?
On Feb 4, 2022, Oppenheimer cuts its price target to $285 from $350, keeps Outperform.
How does Oppenheimer's BIIB target compare with other analysts?
Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50.

More BIIB rating histories

All Oppenheimer ratingsBIIB news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.